Rhenium-186-labeled ortho -hydroxythiobenzhydrazide: a potential theranostic agent for use in metastatic breast cancer | Synapse
April 19, 2026Open Access
Rhenium-186-labeled ortho -hydroxythiobenzhydrazide: a potential theranostic agent for use in metastatic breast cancer
Key Points
The study aims to investigate the potential of rhenium-186-labeled ortho-hydroxythiobenzhydrazide as a theranostic agent for metastatic breast cancer.
Radiolabeling ortho-hydroxythiobenzhydrazide with rhenium-186 using [186Re]ReO4−
Assessment of the radiochemical purity and stability of the [186Re]Re-(htbh)2 complex
Evaluation of the targeting potential for metastatic breast cancer
The [186Re]Re-(htbh)2 complex exhibited high radiochemical purity and stability.
The targeting potential for metastatic breast cancer was confirmed.
Abstract
Ortho -hydroxythiobenzhydrazide was radiolabelled using 186 ReReO 4 − to yield the 186 ReRe-(htbh) 2 complex with high radiochemical purity, stability and targeting potential for metastatic breast cancer.